amisulpride (BARHEMSYS) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Amisulpride is an antiemetic and antipsychotic medication used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; and at higher doses by mouth to treat schizophrenia and acute psychotic episodes. It is sold under the brand names Barhemsys and Solian, Socian, Deniban and others. At very low doses it is also used to treat dysthymia.   Wikipedia

Chemistry

  • SMILES: CCN1CCCC1CNC(=O)c2cc(c(N)cc2OC)S(=O)(=O)CC
  • InChIKey: NTJOBXMMWNYJFB-UHFFFAOYSA-N
  • Mol. Mass: 369.49
  • ALogP: 1.29
  • ChEMBL Molecules:
    amisulpride  
    sultopride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.1799 - $50.1542

United States

$31.8120
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-amino-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide | 4-amino-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide | aminosultopride | amisulprida | amisulpride | amisulpridum | apd421 | barnetil | dan 2163 | deniban | lin 1418 | n-(ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide | solian | solian 100 | solian 200 | solian 400 | solian 50 | sultopride | (+/-)-sultopride | sultopride hcl | sultopride hydrochloride

Organizations (69)

Research & Development (69)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (1)


 

Postoperative Nausea and Vomiting (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Amisulpride (Early Phase 1)

Anorexia Nervosa (Early Phase 1)

Anxiety Disorders (Phase 3)

Bipolar Disorder (Phase 2)

Cognition Disorders (Phase 4)

Dementia (Phase 3)

Depression (Phase 4)

Depressive Disorder, Major (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Gastrointestinal Microbiome (Early Phase 1)

Healthy Volunteers (Phase 1)

Intellectual Disability (Phase 2)

Kidney Failure, Chronic (Phase 1)

Mental Health (Phase 3)

Nausea (Phase 1)

Obsessive-Compulsive Disorder (Phase 1)

Postoperative Nausea and Vomiting (Phase 3)

Psychophysiologic Disorders (Phase 3)

Psychotic Disorders (Phase 4)

Saliva (Phase 3)

Schizophrenia (Phase 4)

Schizophrenia Spectrum and Other Psychotic Disorders (Phase 4)

Schizophrenia, Treatment-Resistant (Phase 4)

Signs and Symptoms (Early Phase 1)

Tardive Dyskinesia (Phase 4)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 67
  • # of Trial Organizations: 69

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue